Sucralfate

Summary

Sucralfate (CHEMBL6067980) is an approved unknown (ATC A02BX02); indicated across 6 conditions including peptic ulcer disease and gastroesophageal reflux disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Unknown
• ATC class: A02BX02
• Indications: 6 conditions
• Clinical trials: 17

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL6067980
Name	Sucralfate
Type	Unknown
Max phase	4
ATC	A02BX02

Also known as: Aluminum sucrose octasulfate, Antepsin, Carafate, Citogel, Hexagastron, Keal, Succosa, Sucralfate, Sucralfate hydrate, Sucralfato, Sucralfin, Sucrate

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

6 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
peptic ulcer disease	4	MONDO:0004247	HP:0004398
gastroesophageal reflux disease	4	MONDO:0007186	EFO:0003948
duodenal ulcer	4	MONDO:0005412	EFO:0004607
esophagitis	2	MONDO:0001409	HP:0100633
eosinophilic esophagitis	0	MONDO:0005361	EFO:0004232

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 17.

Phase distribution

Phase	Trials
PHASE4	7
Not specified	3
PHASE2	2
PHASE3	1
PHASE2/PHASE3	1
PHASE1/PHASE2	1
EARLY_PHASE1	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07257926	PHASE4	NOT_YET_RECRUITING	Prevention of Delayed Post-polypectomy Bleeding by Endoscopic Sucralfate Spray in High-risk Patients: A Randomized Controlled Trial
NCT07312370	PHASE4	NOT_YET_RECRUITING	Esomeprazole Plus Sucralfate for Post-ESD Ulcer Healing
NCT07611162	PHASE4	NOT_YET_RECRUITING	Comparative Effectiveness of Alginate, Magaldrate, Sucralfate, Proton Pump Inhibitors, and Diet in Laryngopharyngeal Reflux Disease
NCT00702871	PHASE4	COMPLETED	A Clinico-Bacteriological Study and Effect of Stress Ulcer Prophylaxis on Occurrence of Ventilator Associated Pneumonia
NCT01284647	PHASE4	COMPLETED	A Study to Evaluate the Efficacy of Teprenone On Chinese Patients With Chronic Non-Atrophic Erosive Gastritis
NCT01613534	PHASE4	COMPLETED	Combined Therapy in Radiation Proctopathy
NCT03635372	PHASE4	COMPLETED	A Comparison of Effectiveness of Oral Sucrolfate, Alginate and Hydrotalcide in Dispeptic Pain Treatment
NCT05369234	PHASE3	COMPLETED	Effects of Oral Aloe Vera Juice on Chemotherapy and Radiation-induced Oral Mucositis and Esophagitis
NCT07310927	PHASE2/PHASE3	COMPLETED	Alginate vs Sucralfate for GERD Symptomatic Relief
NCT05659576	PHASE2	ACTIVE_NOT_RECRUITING	Reducing Acute Upper Gastrointestinal Side-Effects of Thoracic Irradiation
NCT03241030	PHASE2	COMPLETED	Sucralfate to Improve Oral Intake in Children With Infectious Oral Ulcers: a Randomized, Double-blind, Placebo-Controlled Trial
NCT06617026	PHASE1/PHASE2	COMPLETED	Short-Term Outcome of Medical Vs. Surgical Management Of Chronic Anal Fissure
NCT05817656	PHASE1	UNKNOWN	Colonoscopic Sucralfate Spray in Prevention of Delayed Polypectomy Bleeding
NCT02353078	EARLY_PHASE1	COMPLETED	The Effect of Sucralfate Slurry in Patients With Eosinophilic Esophagitis
NCT06107504	Not specified	RECRUITING	Prevention of Post-sphincterotomy Bleeding
NCT02039869	Not specified	WITHDRAWN	Confocal Endomicroscopy for Non-Erosive Reflux Disease (CE NERD)
NCT02788591	Not specified	TERMINATED	Confocal Endomicroscopy for Non-Erosive Reflux Disease Detection

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).